<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Tests of the liver's capacity to transport organic anions and metabolize drugs
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Tests of the liver's capacity to transport organic anions and metabolize drugs
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Tests of the liver's capacity to transport organic anions and metabolize drugs
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence S Friedman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of blood tests are available that reflect the condition of the liver [
         <a href="#rid1">
          1-3
         </a>
         ]. The most common tests used in clinical practice include the serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests are often referred to as "liver function tests," although this term is somewhat misleading since most do not accurately reflect how well the liver is functioning, and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease.
        </p>
        <p>
         Several specialized tests have also been developed (such as
         <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">
          indocyanine green
         </a>
         clearance), which, although uncommonly used in clinical practice, can measure specific aspects of hepatic function [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Despite their limitations, liver biochemical and function tests have many applications in clinical medicine:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They provide a noninvasive method to screen for the presence of liver disease. The serum aminotransferases, for example, used to be part of panel of tests used to screen all blood donors in the United States for the presence of transmissible viruses before specific viral tests became available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They can be used to measure the efficacy of treatments for liver disease (such as immunosuppressant agents for autoimmune hepatitis). (See
         <a class="medical medical_review" href="/z/d/html/3659.html" rel="external">
          "Management of autoimmune hepatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They can be used to monitor the progression of a disease such as viral or alcohol-associated hepatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They can reflect the severity of liver disease, particularly in patients who have cirrhosis. As an example, the Child-Turcotte-Pugh score, which incorporates the prothrombin time and serum bilirubin and albumin concentrations, can predict survival  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         The pattern of abnormalities on these tests is more accurate than any of the individual tests. Elevation of serum aminotransferases indicates hepatocellular injury, while elevation of the serum alkaline phosphatase indicates cholestasis. Recognition of patterns that are consistent with specific diseases can prompt appropriate additional testing.
        </p>
        <p>
         The liver biochemical and function tests that are used commonly in clinical practice and that are used occasionally for specific circumstances can be categorized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tests that detect injury to hepatocytes – Most of these tests measure the activity of hepatic enzymes, such as the aminotransferases, in the circulation. These enzymes are normally intracellular but are released when hepatocytes are injured. (See
         <a class="medical medical_review" href="/z/d/html/3573.html" rel="external">
          "Overview of liver biochemical tests"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tests of the liver's capacity to transport organic anions and metabolize drugs – These tests measure the liver's ability to clear endogenous or exogenous substances from the circulation. The best studied include serum measurements of bilirubin and bile acids and a variety of dynamic tests, including caffeine and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         metabolites, a variety of breath tests, and clearance tests such as bromsulphthalein (BSP) and
         <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">
          indocyanine green
         </a>
         (ICG).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tests of the liver's biosynthetic capacity – The most commonly performed tests to assess the biosynthetic capacity of the liver are the serum albumin and the prothrombin time (which requires the presence of clotting factors produced in the liver). Other tests that have been used are the serum concentrations of lipoproteins, ceruloplasmin, ferritin, and alpha 1-antitrypsin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tests that detect altered immunoregulation, or viral hepatitis – These tests include the immunoglobulins, hepatitis serologies, and specific autoantibodies. Most of these substances are proteins made by B lymphocytes, not by hepatocytes. However, some are quite specific for certain liver diseases, such as antimitochondrial antibodies in primary biliary cholangitis. (See
         <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         This topic review will discuss tests of the liver's capacity to transport organic anions and to metabolize drugs, but will not discuss the serum bilirubin. Most of these tests are used rarely in clinical practice. The other categories of liver biochemical and function tests are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3573.html" rel="external">
          "Overview of liver biochemical tests"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3612.html" rel="external">
          "Enzymatic measures of hepatic cholestasis (alkaline phosphatase, 5'-nucleotidase, gamma-glutamyl transpeptidase)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DYE TESTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because the serum bilirubin is an insensitive and nonspecific measure of hepatobiliary disease, several other tests of hepatic excretory capacity have been developed. These include dye tests, measurement of the serum bile acid concentration, breath tests, and caffeine clearance. Although these tests are more sensitive than the serum bilirubin, they are nonspecific, more difficult to perform, and rarely used.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Bromsulphthalein
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of bromsulphthalein (BSP, sulfobromophthalein sodium) for the assessment of liver function was first introduced in 1924 and continued to be used as an indicator of liver function until the 1970s [
         <a href="#rid5">
          5
         </a>
         ]. BSP is soluble in water, binds rapidly to albumin and alpha-1-lipoprotein after intravenous injection, and is then avidly taken up by hepatocytes [
         <a href="#rid6">
          6
         </a>
         ]. Infusions of BSP have been used to quantify the liver's excretory capacity by measuring the hepatic uptake, storage, and maximal biliary excretion rate of BSP [
         <a href="#rid7">
          7
         </a>
         ]. Similar information can be obtained by determining clearance after a standard intravenous injection [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         BSP is seldom used now, and has been withdrawn from commercial markets due in part to a decline in sales from fear about potentially fatal anaphylactic reactions after intravenous administration [
         <a href="#rid9">
          9
         </a>
         ]. The test is still used occasionally in clinical investigations.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Indocyanine green
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">
          Indocyanine green
         </a>
         (ICG) is another dye that is cleared exclusively by the liver and has been used to evaluate liver function [
         <a href="#rid10">
          10
         </a>
         ]. The principle of ICG clearance is similar to that of BSP except that ICG has a higher hepatic extraction ratio than BSP and is bound to albumin and alpha-1-lipoprotein more avidly [
         <a href="#rid6">
          6,11
         </a>
         ]. ICG has a few other advantages since it is not affected by fever and its clearance is normal in patients with the Dubin-Johnson syndrome and in neonates [
         <a href="#rid10">
          10,12
         </a>
         ].
        </p>
        <p>
         ICG can be measured directly by spectrophotometry. It can also be measured by dichromatic earlobe densitometry [
         <a href="#rid10">
          10
         </a>
         ], but this method is not always reliable and the earlobe readings do not correlate closely with simultaneously obtained plasma values. An ICG meter with a fingertip optical sensor permits continuous measurement of serum ICG concentration [
         <a href="#rid13">
          13
         </a>
         ]. Pulse dye densitometry technology has further improved ICG monitoring [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         ICG clearance can be measured by giving a single intravenous injection (around 0.5 mg/kg) and determining a blood level 15 minutes later [
         <a href="#rid15">
          15
         </a>
         ]. Although these low doses are safe, they are well below the threshold needed to saturate the liver's excretory capacity for ICG, which is more than 72 mmol/kg. As a result, they provide a less accurate measure of hepatic excretory function than BSP clearance. The test is used primarily in Asian rather than Western countries.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Use for estimating hepatic blood flow
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICG provides a good estimate of hepatic blood flow [
         <a href="#rid16">
          16
         </a>
         ]. Infusion of ICG at a rate below the liver's capacity to clear it leads to a steady state within one hour, at which time the clearance rate is equal to the infusion rate. Hepatic blood flow can be estimated by use of the Fick equation:
        </p>
        <p>
         Estimated hepatic blood flow = R ÷ ([ICGa] - [ICGhv])
        </p>
        <p>
         where R equals the hepatic removal rate of ICG, which equals the infusion rate at steady state, and ICGa and ICGhv equal the concentration of ICG in the hepatic artery and portal vein blood and in hepatic vein blood, respectively. ICGa is the same as the ICG concentration in peripheral venous blood since other organs do not clear ICG. It is impractical to obtain a direct measurement of ICGhv in most circumstances since it requires catheterization of the hepatic vein. Instead, the hepatic clearance rate is usually assumed to be 100 percent (because first-pass extraction of ICG by the liver is high), and therefore ICGhv is considered to be zero.
        </p>
        <p>
         Although this method permits noninvasive testing, it underestimates hepatic blood flow because ICGhv is always more than zero when actually measured [
         <a href="#rid16">
          16
         </a>
         ]. Despite this limitation, ICG infusion provides a good approximation of blood flow in healthy adults, but not in patients with cirrhosis who have a marked decrease in extraction of ICG [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Use in liver transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A potential role for ICG elimination for optimizing use (estimating the optimal dose) of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         after liver transplantation has been suggested [
         <a href="#rid19">
          19
         </a>
         ]. In another report, the addition of ICG measurement to the Model for End-stage Liver Disease (MELD) score improved the prediction of survival in patients with advanced cirrhosis compared with the standard MELD score or the MELD score combined with plasma sodium concentration (MELD-Na) [
         <a href="#rid20">
          20
         </a>
         ]. With the availability of improved ICG monitoring, ICG clearance continues to be studied, particularly after liver transplantation and hepatic resection [
         <a href="#rid14">
          14,21-23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SERUM BILE ACID CONCENTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although sensitive tests to measure the serum bile acid concentration have been available for many years, their role in the evaluation of patients with suspected liver disease is not well established. Measurement of serum bile acids (cholic and chenodeoxycholic acids and their conjugates) may be helpful in patients with primary biliary cholangitis and primary sclerosing cholangitis and in women who are suspected of having intrahepatic cholestasis of pregnancy (ICP). (See
         <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">
          "Intrahepatic cholestasis of pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Physiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bile acids are synthesized from cholesterol in hepatocytes, conjugated to glycine or taurine, and then secreted into bile. Approximately 80 to 90 percent of the secreted pool of bile acids is stored in the gallbladder between meals. The remaining 10 to 20 percent is secreted continuously into the duodenum, which accounts for the bile acids normally present in serum after a long fast (concentration of approximately 5 to 10 micromoles/L) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         The gallbladder contracts and discharges its pool of bile acids into the duodenum during a meal. Bile acids move rapidly down the intestinal tract, where they are actively absorbed by carrier-mediated transport in the terminal ileum and carried back to the liver by way of the portal vein [
         <a href="#rid25">
          25
         </a>
         ]. A small proportion of bile acids are absorbed in the more proximal small intestine and colon by nonionic passive diffusion, and some pass into the feces.
        </p>
        <p>
         The net effect of this enterohepatic recirculation is that a larger quantity of bile acids reaches the liver after a meal, and since the proportion extracted by the liver is constant, there is a two to fivefold elevation in the serum bile acid concentration compared with fasting values [
         <a href="#rid26">
          26
         </a>
         ]. In healthy individuals, serum bile acids are derived entirely from intestinal input; none comes directly from the liver [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         As a result of these processes, the serum bile acid concentration is affected by a number of factors including hepatic blood flow, hepatic uptake, secretion of bile acids, intestinal motility, and the intestinal microbiota [
         <a href="#rid25">
          25,28
         </a>
         ]. Ethnicity and diseases that influence any of these functions can alter the serum bile acid concentration [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Measurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several accurate methods to measure the serum bile acid concentration. These include enzymatic assays in which the bacterial enzyme 3-alpha-hydroxysteroid dehydrogenase is coupled to either fluorometric [
         <a href="#rid30">
          30
         </a>
         ] or bioluminescence assays [
         <a href="#rid31">
          31
         </a>
         ], gas-liquid chromatography [
         <a href="#rid32">
          32
         </a>
         ], radioimmunoassay [
         <a href="#rid33">
          33,34
         </a>
         ], and a highly specific assay combining gas-liquid chromatography and mass spectrometry [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Only the enzyme assays and radioimmunoassays can be performed easily by the clinical chemistry laboratory. Although the radioimmunoassays can be automated, a variety of individual radioimmunoassays that detect cholic and chenodeoxycholic acids and their conjugates would have to be used to measure the total concentration of bile acids in serum. This is usually not necessary if the purpose of the assay is to detect liver disease.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Clinical significance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum bile acid concentration may be disproportionately elevated in certain cholestatic liver diseases.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum total bile acid concentrations can increase by 10- to 100-fold in intrahepatic cholestasis of pregnancy, and may be the first or only laboratory abnormality [
         <a href="#rid36">
          36
         </a>
         ]. Serum cholic acid rises more than chenodeoxycholic acid, resulting in a marked elevation of the cholic/chenodeoxycholic acid ratio compared with pregnant women without intrahepatic cholestasis [
         <a href="#rid37">
          37
         </a>
         ]. The ratio of glycine to taurine conjugates is decreased. However, the diagnostic accuracy of serum bile acid measurements in intrahepatic cholestasis of pregnancy may be overestimated [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">
          "Intrahepatic cholestasis of pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum bile acid levels are increased 25-fold in some patients with primary biliary cholangitis and primary sclerosing cholangitis [
         <a href="#rid39">
          39
         </a>
         ]. Furthermore, the response to treatment with
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          ursodeoxycholic acid
         </a>
         can be monitored by measuring the concentrations of the different serum bile acids. With an adequate dose, ursodeoxycholic acid should eventually constitute approximately 50 percent of serum bile acids [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">
          "Overview of the management of primary biliary cholangitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         As might be expected, the serum bile acid concentration is more sensitive than the serum bilirubin for all types of hepatobiliary disorders [
         <a href="#rid41">
          41,42
         </a>
         ] and is as sensitive as serum aminotransferases in detecting acute viral hepatitis [
         <a href="#rid43">
          43
         </a>
         ]. However, the serum bile acid concentration is less sensitive than serum aminotransferases as a screening test for detecting subclinical liver disease [
         <a href="#rid44">
          44,45
         </a>
         ]. Serum bile acid levels are normal in patients with Gilbert syndrome [
         <a href="#rid46">
          46,47
         </a>
         ] and Dubin-Johnson syndrome [
         <a href="#rid48">
          48
         </a>
         ], which may help to confirm these diagnoses.
        </p>
        <p>
         The serum bile acid profile is invariably abnormal in cirrhosis of any cause [
         <a href="#rid42">
          42,49
         </a>
         ], a change that is as or more sensitive than the serum albumin or prothrombin time. This is due to the decrease in functioning liver cell mass, decrease in bile excretion, and portosystemic shunting usually present in chronic liver diseases, all of which affect serum bile acid levels.
        </p>
        <p>
         It was once suggested that serum bile acid testing could predict histologic severity and might replace percutaneous liver biopsy in chronic hepatitis [
         <a href="#rid50">
          50
         </a>
         ]. However, other investigators have found a poor correlation between serum bile acids and histologic severity in chronic hepatitis and alcohol-associated liver disease [
         <a href="#rid41">
          41,51,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          BREATH TESTS AND CLEARANCE TESTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breath tests were introduced as a practical means for evaluating hepatic functional reserve. Many breath tests are available, including 14C-aminopyrine [
         <a href="#rid53">
          53
         </a>
         ], 14C- or 13C-galactose [
         <a href="#rid54">
          54
         </a>
         ], 14C-phenacetin [
         <a href="#rid55">
          55
         </a>
         ], 14C-diazepam [
         <a href="#rid56">
          56
         </a>
         ] and 13C-methacetin [
         <a href="#rid57">
          57,58
         </a>
         ] breath tests. Other tests, such as the clearance of galactose or caffeine or the formation of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         metabolites, can provide similar information.
        </p>
        <p>
         Although breath tests have been available for many years in the United States, they are still used infrequently since they are less convenient to perform than a simple blood test [
         <a href="#rid59">
          59
         </a>
         ]. The equipment needed to perform the tests is not widely available [
         <a href="#rid60">
          60
         </a>
         ]. Furthermore, diagnostic tests using 14C cannot be performed in children.
        </p>
        <p>
         The principles and methodology underlying all of the breath tests are similar. A substance known to be metabolized primarily in the liver is labeled with 14C or 13C and is given orally or parenterally. As long as absorption is complete or reproducible, the oral route is more convenient. The labeled CO
         <sub>
          2
         </sub>
         exhaled in the breath is collected at various intervals in an alkaline medium that serves as a CO
         <sub>
          2
         </sub>
         trap. Metabolism of the labeled agent by the liver can be determined semiquantitatively by multiplication of the specific activity of exhaled 14CO
         <sub>
          2
         </sub>
         over a given time interval by a value for endogenous CO
         <sub>
          2
         </sub>
         output of 9 mmol/kg per hour.
        </p>
        <p>
         An ideal drug for use in a breath test of hepatic drug-metabolizing capacity should have the following characteristics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The test drug must be metabolized primarily by the liver, a property which is often difficult to validate in humans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When the drug is given orally, its absorption must be rapid and complete or at least predictable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The drug should have a low hepatic extraction ratio (about 20 to 30 percent) so that changes in hepatic blood flow have little influence on its clearance from blood.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The generated 14CO
         <sub>
          2
         </sub>
         should be distributed evenly in the body and not sequestered in an unavailable compartment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For ease of collection of 14CO
         <sub>
          2
         </sub>
         , the drug should have a short elimination half-life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The drug must be safe.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Aminopyrine breath test
         </span>
         <span class="headingEndMark">
          —
         </span>
         The greatest experience has been obtained with the 14C-aminopyrine breath test, which measures microsomal hepatic function [
         <a href="#rid61">
          61
         </a>
         ]. The radioactive methyl groups of aminopyrine undergo demethylation and are eventually converted to formaldehyde, formate, and bicarbonate with exhalation of 14CO
         <sub>
          2
         </sub>
         in breath.
        </p>
        <p>
         Studies in rats and humans have shown that the rate of 14CO
         <sub>
          2
         </sub>
         appearance in breath correlates with the hepatic mixed-function oxidase system mass [
         <a href="#rid53">
          53,62,63
         </a>
         ]. The rate of 14CO
         <sub>
          2
         </sub>
         appearance can be influenced by drugs that affect this system, increasing after pretreatment with
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         , which induces microsomal enzymes, and decreasing after the administration of
         <a class="drug drug_general" data-topicid="9379" href="/z/d/drug information/9379.html" rel="external">
          disulfiram
         </a>
         , which inhibits microsomal enzymes [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         The presumption that the breath test is a measure of functioning hepatic microsomal mass is further supported by observations that patients with hepatocellular disease have low rates of 14CO
         <sub>
          2
         </sub>
         excretion, which correlate well with other tests that reflect functional mass (such as the prothrombin time, albumin, and serum bile acid concentration) [
         <a href="#rid50">
          50,53,63-65
         </a>
         ]. Reduced aminopyrine breath test results also correlate well with the degree of necrosis and inflammation in liver biopsy specimens from patients with alcohol-associated cirrhosis [
         <a href="#rid64">
          64
         </a>
         ] and with the presence of inflammation in patients with nonalcoholic fatty liver disease [
         <a href="#rid66">
          66
         </a>
         ]. A similar test that uses 13C is also available and avoids exposure to radioactivity [
         <a href="#rid67">
          67,68
         </a>
         ]. However, its use requires sophisticated and expensive mass spectrometers, which are not widely available.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Method
         </span>
         <span class="headingEndMark">
          —
         </span>
         The aminopyrine breath test is usually performed after an overnight fast. A known dose of 14 or 13 C-aminopyrine is administered orally and breath samples are collected at 30-minute intervals for up to four hours. The expired CO
         <sub>
          2
         </sub>
         is trapped in alkali and counted. There is an excellent correlation between the percentage of administered 14C expired in two hours, the plasma clearance rate of aminopyrine, and the fractional disappearance rate of 14CO
         <sub>
          2
         </sub>
         [
         <a href="#rid69">
          69
         </a>
         ]. As a result, it is usually satisfactory to rely upon a single sample collected at two hours. However, a single measurement at 60 minutes is more convenient for patients, and yields similar information [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Normal subjects excrete 6.6 ± 1.3 percent of the administered dose in the breath in two hours. The value is significantly lower in patients with hepatocellular injury. The results can be influenced by diet, folate deficiency, and use of other drugs.
        </p>
        <p>
         The 13C-aminopyrine test is performed with serial breath samples obtained every 30 minutes for three hours [
         <a href="#rid67">
          67
         </a>
         ]. Results are expressed as the percentage of the administered dose recovered over time.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Clinical significance
         </span>
         <span class="headingEndMark">
          —
         </span>
         A single breath result cannot distinguish among different types of liver diseases. The degree of depression of breath test results overlaps considerably in all types of liver disease, including cirrhosis, hepatitis, hepatic cancer, and various histologic forms of alcohol-associated liver disease [
         <a href="#rid63">
          63,70,71
         </a>
         ]. The test has been reported to have clinical value in quantifying residual functioning liver cell mass and in establishing prognosis in diseases such as alcohol-associated hepatitis [
         <a href="#rid70">
          70
         </a>
         ], but it does not correlate with changes in the Child-Pugh class after transarterial chemoembolization in patients with hepatocellular carcinoma [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         The aminopyrine breath test appears to be as sensitive for the detection of hepatocellular disease as the serum aminotransferases and more sensitive than the prothrombin time and serum bilirubin and albumin concentrations [
         <a href="#rid60">
          60,71
         </a>
         ]. It may be more specific for detecting histologic severity in chronic hepatitis and alcohol-associated liver disease than conventional liver biochemical and function tests [
         <a href="#rid64">
          64,73
         </a>
         ]. Sensitivity and specificity were 86 and 68 percent for detecting cirrhosis in a study of 61 patients with various causes of liver disease (of whom 21 had compensated cirrhosis) undergoing the 13C breath test [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         The results may also correlate with survival in patients with alcohol-associated hepatitis [
         <a href="#rid74">
          74
         </a>
         ] and progression of fibrosis in patients with chronic hepatitis C [
         <a href="#rid75">
          75
         </a>
         ]. In one study, for example, the aminopyrine breath test predicted short-term survival and clinical improvement of patients with alcohol-associated hepatitis more reliably than conventional liver biochemical and function tests [
         <a href="#rid74">
          74
         </a>
         ]. However, studies evaluating the utility of the aminopyrine breath test for predicting survival in patients with cirrhosis have produced conflicting results [
         <a href="#rid76">
          76-79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Galactose clearance and breath test
         </span>
         <span class="headingEndMark">
          —
         </span>
         Galactose clearance is another method to estimate functional hepatic mass and cytosolic hepatic function [
         <a href="#rid80">
          80
         </a>
         ]. After intravenous administration of galactose (0.5 mg/kg), serial blood samples are collected and assayed. The rate of galactose clearance is markedly reduced in patients with cirrhosis and chronic hepatitis but is rarely abnormal in patients with biliary obstruction [
         <a href="#rid81">
          81
         </a>
         ]. Galactose clearance has been proposed as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         A breath test has also been developed using 14C-galactose [
         <a href="#rid54">
          54
         </a>
         ], producing results similar to the intravenous galactose clearance test. However, the utility of these tests is uncertain. Neither is better than the serum albumin in distinguishing healthy subjects from patients with cirrhosis [
         <a href="#rid54">
          54,83
         </a>
         ], and galactose clearance appears to add little to standard laboratory studies in predicting outcome in patients with acute liver failure [
         <a href="#rid84">
          84
         </a>
         ] or cirrhosis [
         <a href="#rid85">
          85,86
         </a>
         ].
        </p>
        <p>
         A 13C-galactose breath test is also available. The sensitivity and specificity for detecting cirrhosis were 71 and 85 percent, respectively, in a study of 61 patients with various causes of liver disease (21 of whom had compensated cirrhosis) [
         <a href="#rid67">
          67
         </a>
         ]. These values were 100 and 93 percent, respectively, when combined with the results of a 13C-aminopyrine breath test.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Caffeine clearance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of the rate of caffeine clearance is another method to quantify functional hepatic capacity and microsomal function [
         <a href="#rid87">
          87
         </a>
         ]. The test is usually performed by the ingestion of oral caffeine (280 to 366 mg) followed by measurement of the plasma caffeine concentration at 1, 2, 3, 6, 12 and 24 hours [
         <a href="#rid88">
          88,89
         </a>
         ]. In a variation of the method, caffeine is taken at noon and the concentration of caffeine is measured from samples of saliva collected at bedtime and the next morning upon awakening [
         <a href="#rid89">
          89
         </a>
         ]. Caffeine can also be measured in scalp hair [
         <a href="#rid90">
          90
         </a>
         ] and (using 13C-caffeine) in breath [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         The results of caffeine clearance tests are similar to those obtained with the 14C-aminopyrine test without the need for radioisotopes or breath collections. The test can distinguish decompensated cirrhosis from noncirrhotic liver disease but does not correlate with the Child-Pugh class or MELD score [
         <a href="#rid92">
          92
         </a>
         ]. Smoking is a confounding factor, since it increases caffeine clearance, while increasing age and certain drugs may reduce caffeine clearance [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Lidocaine metabolite formation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tests of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         metabolism take advantage of the conversion of lidocaine to monoethylglycinexylidide (MEGX) within the hepatic cytochrome P450 system. Fifteen minutes after the intravenous administration of lidocaine (1 mg/kg), a serum sample is taken for determination of the MEGX concentration, which is measured using a fluorescence polarization immunoassay [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         Numerous studies have assessed the prognostic value of this test. In one, the survival of patients with cirrhosis who had MEGX concentrations greater than 30 ng/mL serum was significantly greater than that of patients with lower values [
         <a href="#rid94">
          94
         </a>
         ]. Another study found that a decline in the MEGX concentration correlated with histologic worsening of chronic hepatitis and cirrhosis and may therefore provide a noninvasive means of following the course of chronic liver disease [
         <a href="#rid95">
          95
         </a>
         ]. A limitation of the test is inhibition by co-administered drugs that are also metabolized by cytochrome P450 3A4 [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
         The MEGX test may also have a role in identifying suitable organs for liver transplantation. Good early graft function has been associated with higher donor MEGX concentrations 15 minutes after the infusion of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         [
         <a href="#rid97">
          97-99
         </a>
         ]. Unfortunately, overlapping values [
         <a href="#rid99">
          99
         </a>
         ] and the shortage of organs currently make this approach impractical.
        </p>
        <p class="headingAnchor" id="H265468047">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum liver biochemical tests
         </strong>
         – A number of blood tests are available that reflect the condition of the liver. The most common tests used in clinical practice include the serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests are often referred to as "liver function tests," although this term is somewhat misleading since most do not accurately reflect how well the liver is functioning and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dye tests
         </strong>
         – Because the serum bilirubin is an insensitive and nonspecific measure of hepatobiliary disease, several other tests of hepatic excretory capacity have been developed. These include dye tests, measurement of the serum bile acid concentration, breath tests, and caffeine clearance. Although these tests are more sensitive than the serum bilirubin, they are nonspecific, more difficult to perform, and rarely used. (See
         <a class="local">
          'Dye tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum bile acid concentration
         </strong>
         – Although sensitive tests to measure the serum bile acid concentration have been available for many years, their role in the evaluation of patients with suspected liver disease is not well established. Measurement of serum bile acids (cholic and chenodeoxycholic acids and their conjugates) may be helpful for early diagnosis in patients with primary biliary cholangitis and primary sclerosing cholangitis and in women who are suspected of having intrahepatic cholestasis of pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/3560.html" rel="external">
          "Intrahepatic cholestasis of pregnancy"
         </a>
         and
         <a class="local">
          'Serum bile acid concentration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breath tests and clearance tests
         </strong>
         – Breath tests were introduced as a practical means for evaluating hepatic functional reserve. Many breath tests are available, including 14C-aminopyrine, 4C- or 13C-galactose, 14C-phenacetin, 14C-diazepam, and 13C methacetin breath tests. Other tests, such as the clearance of galactose or caffeine or the formation of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         metabolites, can provide similar information. Although breath tests have been available for a number of years in the United States, they are used infrequently since they are less convenient to perform than a simple blood test. The equipment needed to perform these tests is not widely available. (See
         <a class="local">
          'Breath tests and clearance tests'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018; 67:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreiner AD, Rockey DC. Evaluation of abnormal liver tests in the adult asymptomatic patient. Curr Opin Gastroenterol 2018; 34:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017; 112:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mousa OY, Kamath PS. A History of the Assessment of Liver Performance. Clin Liver Dis (Hoboken) 2021; 18:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenthal SM, White EC. Studies in the value of selected phthalein compounds in the estimation of hepatic function. J Pharmacol Exp Ther 1924; 24:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker KJ. Binding of sulfobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma alpha-1 lipoproteins. Proc Soc Exp Biol Med 1966; 122:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WHEELER HO, MELTZER JI, BRADLEY SE. Biliary transport and hepatic storage of sulfobromophthalein sodium in the unanesthetized dog, in normal man, and in patients with hepatic disease. J Clin Invest 1960; 39:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Häcki W, Bircher J, Preisig R. A new look at the plasma disappearance of sulfobromophthalein (BSP): correlation with the BSP transport maximum and the hepatic plasma flow in man. J Lab Clin Med 1976; 88:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           IBER FL. REACTIONS TO SULFOBROMOPHTHALEIN SODIUM INJECTION, USP2. Bull Johns Hopkins Hosp 1965; 116:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LEEVY CM, BENDER J. PHYSIOLOGY OF DYE EXTRACTION BY THE LIVER: COMPARATIVE STUDIES OF SULFOBROMOPHTHALEIN AND INDOCYANINE GREEN. Ann N Y Acad Sci 1963; 111:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CHERRICK GR, STEIN SW, LEEVY CM, DAVIDSON CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest 1960; 39:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dejeux JF. Hepatic clearance and biliary excretion of unconjugated dyes in the Dubin-Johnson syndrome. Gut 1971; 12:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanda M, Taniguchi K, Awazu K. Continuous monitoring of cardiogreen removal by a diseased liver using an optical sensor. Proc SPIE 1988; 904:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Gasperi A, Mazza E, Prosperi M. Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery? World J Hepatol 2016; 8:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Møller S, la Cour Sibbesen E, Madsen JL, Bendtsen F. Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease. J Gastroenterol Hepatol 2019; 34:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bircher J. Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis 1983; 3:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wynne HA, Goudevenos J, Rawlins MD, et al. Hepatic drug clearance: the effect of age using indocyanine green as a model compound. Br J Clin Pharmacol 1990; 30:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skak C, Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver 1987; 7:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker BM, Cywinski JB, Alster JM, et al. Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation. Liver Transpl 2008; 14:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zipprich A, Kuss O, Rogowski S, et al. Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut 2010; 59:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olmedilla L, Lisbona CJ, Pérez-Peña JM, et al. Early Measurement of Indocyanine Green Clearance Accurately Predicts Short-Term Outcomes After Liver Transplantation. Transplantation 2016; 100:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Roy B, Grégoire E, Cossé C, et al. Indocyanine Green Retention Rates at 15 min Predicted Hepatic Decompensation in a Western Population. World J Surg 2018; 42:2570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kokudo T, Hasegawa K, Shirata C, et al. Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. Liver Cancer 2019; 8:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahlberg J, Angelin B, Björkhem I, Einarsson K. Individual bile acids in portal venous and systemic blood serum of fasting man. Gastroenterology 1977; 73:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry W, Reichen J. Bile acid metabolism: its relation to clinical disease. Semin Liver Dis 1983; 3:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaRusso NF, Korman MG, Hoffman NE, Hofmann AF. Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption. N Engl J Med 1974; 291:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaRusso NF, Hoffman NE, Korman MG, et al. Determinants of fasting and postprandial serum bile acid levels in healthy man. Am J Dig Dis 1978; 23:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mouzaki M, Wang AY, Bandsma R, et al. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One 2016; 11:e0151829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo L, Aubrecht J, Li D, et al. Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PLoS One 2018; 13:e0193824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes S, Spenney JG. Improved enzymatic assays for bile acids using resazurin and NADH oxidoreductase from Clostridium kluyveri. Clin Chim Acta 1980; 102:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roda A, Kricka LJ, DeLuca M, Hofmann AF. Bioluminescence measurement of primary bile acids using immobilized 7 alpha-hydroxysteroid dehydrogenase: application to serum bile acids. J Lipid Res 1982; 23:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pennington CR, Ross PE, Bouchier IA. Serum bile acids in the diagnosis of hepatobiliary disease. Gut 1977; 18:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demers LM, Hepner G. Radioimmunoassay of bile acids in serum. Clin Chem 1976; 22:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schalm SW, van Berge-Henegouwen GP, Hofmann AF, et al. Radioimmunoassay of bile acids: development, validation, and preliminary application of an assay for conjugates of chenodeoxycholic acid. Gastroenterology 1977; 73:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angelin B, Bjökhem I, Einarsson K. Individual serum bile acid concentrations in normo- and hyperlipoproteinemia as determined by mass fragmentography: relation to bile acid pool size. J Lipid Res 1978; 19:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunzer M, Barnes P, Byth K, O'Halloran M. Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis. Gastroenterology 1986; 91:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brites D, Rodrigues CM, Oliveira N, et al. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998; 28:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manzotti C, Casazza G, Stimac T, et al. Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev 2019; 7:CD012546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batta AK, Arora R, Salen G, et al. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 1989; 30:1953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poupon RE, Chrétien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milstein HJ, Bloomer JR, Klatskin G. Serum bile acids in alcoholic liver disease. Comparison with histological features of the disease. Am J Dig Dis 1976; 21:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skrede S, Solberg HE, Blomhoff JP, Gjone E. Bile acids measured in serum during fasting as a test for liver disease. Clin Chem 1978; 24:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishler JM 4th, Barbosa L, Mihalko LJ, McCarter H. Serum bile acids and alanine aminotransferase concentrations. Comparison of efficacy as indirect means of identifying carriers of non-A, non-B hepatitis agents and of onset, severity, and duration of posttransfusion non-A, non-B hepatitis in recipients. JAMA 1981; 246:2340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferraris R, Colombatti G, Fiorentini MT, et al. Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases. Sensitivity, specificity, and predictive value. Dig Dis Sci 1983; 28:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rickers H, Christensen M, Arnfred T, et al. The diagnostic value of fasting serum total bile acid concentration in patients with suspected liver disease. A prospective, consecutive study. Scand J Gastroenterol 1982; 17:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roda A, Roda E, Sama C, et al. Serum primary bile acids in Gilbert's syndrome. Gastroenterology 1982; 82:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briheim G, Frydén A, Tobiasson P. Serum bile acids in Gilbert's syndrome before and after reduced caloric intake. Scand J Gastroenterol 1982; 17:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alpert S, Mosher M, Shanske A, Arias IM. Multiplicity of hepatic excretory mechanisms for organic anions. J Gen Physiol 1969; 53:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Festi D, Morselli Labate AM, Roda A, et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology 1983; 3:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monroe PS, Baker AL, Schneider JF, et al. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982; 2:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einarsson K, Angelin B, Björkhem I, Glaumann H. The diagnostic value of fasting individual serum bile acids in anicteric alcoholic liver disease: relation to liver morphology. Hepatology 1985; 5:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones MB, Weinstock S, Koretz RL, et al. Clinical value of serum bile acid levels in chronic hepatitis. Dig Dis Sci 1981; 26:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 1974; 291:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shreeve WW, Shoop JD, Ott DG, McInteer BB. Test for alcoholic cirrhosis by conversion of [14C]- or [13C]galactose to expired CO2. Gastroenterology 1976; 71:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breen KJ. 14C-phenacetin breath test in the assessment of hepatic function. Gastroenterology 1977; 72:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hepner GW, Vesell ES, Lipton A, et al. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med 1977; 90:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorowska-Kowolik K, Chobot A, Kwiecien J. 13C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application. Gastroenterol Res Pract 2017; 2017:7397840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontana RJ, Stravitz RT, Durkalski V, et al. Prognostic Value of the 13 C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury. Hepatology 2021; 74:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stravitz RT, Ilan Y. Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic? Liver Int 2017; 37:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofman A. The aminopyrine demethylation breath test and the serum bile acid level: Nominated but not yet elected to join the common liver tests. Hepatology 1982; 4:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pijls KE, de Vries H, Nikkessen S, et al. Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited. Liver Int 2014; 34:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauterburg BH, Bircher J. Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat. J Pharmacol Exp Ther 1976; 196:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med 1975; 83:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlisle R, Galambos JT, Warren WD. The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig Dis Sci 1979; 24:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bircher J, Küpfer A, Gikalov I, Preisig R. Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 1976; 20:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lykke Eriksen P, Sørensen M, Grønbæk H, et al. Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. Clin Res Hepatol Gastroenterol 2019; 43:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini EG, Fasoli A, Borro P, et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini E, Fasoli A, Chiarbonello B, et al. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hepner GW, Vesell ES. Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease. Clin Pharmacol Ther 1976; 20:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker AL, Kotake AN, Schoeller DA. Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis 1983; 3:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galizzi J, Long RG, Billing BH, Sherlock S. Assessment of the (14C) aminopyrine breath test in liver disease. Gut 1978; 19:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schütte K, Seidensticker R, Milbradt O, et al. Assessment and monitoring of liver function by ¹³C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma. Z Gastroenterol 2015; 53:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monroe P, Baker AL, Glagov S, Sitrin M. Management of liver failure in a patient following jejunoileal bypass. Gastroenterology 1980; 78:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider JF, Baker AL, Haines NW, et al. Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980; 79:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocco A, de Nucci G, Valente G, et al. 13C-aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. J Hepatol 2012; 56:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill RA, Goodman MW, Golfus GR, et al. Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg 1983; 198:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry DA, Kitchingman G, Langman MJ. [14C]Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Dig Dis Sci 1985; 30:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebossé F, Guillaud O, Forestier J, et al. Prognostic Value of Metabolic Liver Function Tests: a Study on 711 Cirrhotic Patients. J Gastrointestin Liver Dis 2016; 25:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petta S, Rini F, Calvaruso V, et al. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. Liver Int 2020; 40:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by a single injection. Scand J Lab Clin Invest 1966; 18(Suppl 92):118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tengström B. The discriminatory ability of a galactose tolerance test and some other tests in the diagnosis of cirrhosis of the liver, hepatitis and biliary obstruction. Scand J Clin Lab Invest 1969; 23:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt LE, Ott P, Tygstrup N. Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience. Clin Gastroenterol Hepatol 2004; 2:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           TYGSTRUP N. THE GALACTOSE ELIMINATION CAPACITY IN RELATION TO CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH CIRRHOSIS. Acta Med Scand 1964; 175:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen E, Bremmelgaard A, Bahnsen M, et al. Prediction of fatality in fulminant hepatic failure. Scand J Gastroenterol 1984; 19:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gluud C, Henriksen JH, Nielsen G. Prognostic indicators in alcoholic cirrhotic men. Hepatology 1988; 8:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renner E, Wietholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joeres R, Klinker H, Heusler H, et al. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology 1988; 8:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jost G, Wahlländer A, von Mandach U, Preisig R. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 1987; 7:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizuno A, Uematsu T, Gotoh S, et al. The measurement of caffeine concentration in scalp hair as an indicator of liver function. J Pharm Pharmacol 1996; 48:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park GJ, Katelaris PH, Jones DB, et al. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 2003; 38:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinou D, Margariti E, Hadziyannis E, et al. Significance of the (13)C-caffeine breath test for patients with cirrhosis. Ann Gastroenterol 2014; 27:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oellerich M, Raude E, Burdelski M, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987; 25:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiffman ML, Luketic VA, Sanyal AJ, et al. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology 1994; 19:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Ou-Yang QG, Huang WL, et al. Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. Drug Des Devel Ther 2020; 14:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oellerich M, Burdelski M, Ringe B, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; 1:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oellerich M, Burdelski M, Ringe B, et al. Functional state of the donor liver and early outcome of transplantation. Transplant Proc 1991; 23:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zotz RB, von Schönfeld J, Erhard J, et al. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors. Transplantation 1997; 63:538.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3572 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29122851" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Guidelines on the management of abnormal liver blood tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29697467" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Evaluation of abnormal liver tests in the adult asymptomatic patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27995906" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34745582" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A History of the Assessment of Liver Performance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Studies in the value of selected phthalein compounds in the estimation of hepatic function
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5918158" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Binding of sulfobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma alpha-1 lipoproteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13844286" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Biliary transport and hepatic storage of sulfobromophthalein sodium in the unanesthetized dog, in normal man, and in patients with hepatic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/993641" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A new look at the plasma disappearance of sulfobromophthalein (BSP): correlation with the BSP transport maximum and the hepatic plasma flow in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14261146" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : REACTIONS TO SULFOBROMOPHTHALEIN SODIUM INJECTION, USP2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14085840" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : PHYSIOLOGY OF DYE EXTRACTION BY THE LIVER: COMPARATIVE STUDIES OF SULFOBROMOPHTHALEIN AND INDOCYANINE GREEN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13809697" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hepatic clearance and biliary excretion of unconjugated dyes in the Dubin-Johnson syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Continuous monitoring of cardiogreen removal by a diseased liver using an optical sensor
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26981173" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30221390" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6359423" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Quantitative assessment of deranged hepatic function: a missed opportunity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2291878" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hepatic drug clearance: the effect of age using indocyanine green as a model compound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3613884" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18161838" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20581243" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26569066" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Early Measurement of Indocyanine Green Clearance Accurately Predicts Short-Term Outcomes After Liver Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29340728" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Indocyanine Green Retention Rates at 15 min Predicted Hepatic Decompensation in a Western Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31799202" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/913977" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Individual bile acids in portal venous and systemic blood serum of fasting man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6359428" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Bile acid metabolism: its relation to clinical disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4851463" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/677089" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Determinants of fasting and postprandial serum bile acid levels in healthy man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27203081" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29513725" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6892796" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Improved enzymatic assays for bile acids using resazurin and NADH oxidoreductase from Clostridium kluyveri.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6962270" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Bioluminescence measurement of primary bile acids using immobilized 7 alpha-hydroxysteroid dehydrogenase: application to serum bile acids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/590851" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Serum bile acids in the diagnosis of hepatobiliary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1261008" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Radioimmunoassay of bile acids in serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/873130" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Radioimmunoassay of bile acids: development, validation, and preliminary application of an assay for conjugates of chenodeoxycholic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/670831" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Individual serum bile acid concentrations in normo- and hyperlipoproteinemia as determined by mass fragmentography: relation to bile acid pool size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3743960" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9537870" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31283001" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2621422" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8477964" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1274919" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Serum bile acids in alcoholic liver disease. Comparison with histological features of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/657487" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Bile acids measured in serum during fasting as a test for liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6795368" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Serum bile acids and alanine aminotransferase concentrations. Comparison of efficacy as indirect means of identifying carriers of non-A, non-B hepatitis agents and of onset, severity, and duration of posttransfusion non-A, non-B hepatitis in recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6825534" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases. Sensitivity, specificity, and predictive value.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7134884" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The diagnostic value of fasting serum total bile acid concentration in patients with suspected liver disease. A prospective, consecutive study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7053338" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Serum primary bile acids in Gilbert's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7156881" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Serum bile acids in Gilbert's syndrome before and after reduced caloric intake.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5764745" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Multiplicity of hepatic excretory mechanisms for organic anions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6618438" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7076113" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3967851" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The diagnostic value of fasting individual serum bile acids in anicteric alcoholic liver disease: relation to liver morphology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7297378" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical value of serum bile acid levels in chronic hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4427643" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1278655" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Test for alcoholic cirrhosis by conversion of [14C]- or [13C]galactose to expired CO2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : 14C-phenacetin breath test in the assessment of hepatic function
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/894100" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28757868" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : 13C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33660316" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prognostic Value of the 13 C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27718326" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The aminopyrine demethylation breath test and the serum bile acid level: Nominated but not yet elected to join the common liver tests
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24428683" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1255494" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1200495" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/378624" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/975720" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Aminopyrine demethylation measured by breath analysis in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30770336" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15765448" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929389" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/991536" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6359427" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Clinical utility of breath tests for the assessment of hepatic function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/624504" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Assessment of the (14C) aminopyrine breath test in liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25594703" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Assessment and monitoring of liver function by¹³C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7372075" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Management of liver failure in a patient following jejunoileal bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6777231" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22173159" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : 13C-aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6639175" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Aminopyrine breath test predicts surgical risk for patients with liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3928286" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : [14C]Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27689198" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Prognostic Value of Metabolic Liver Function Tests: a Study on 711 Cirrhotic Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31507057" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Determination of the hepatic elimination capacity (Lm) of galactose by a single injection
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5372446" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The discriminatory ability of a galactose tolerance test and some other tests in the diagnosis of cirrhosis of the liver, hepatitis and biliary obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15118981" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14136244" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : THE GALACTOSE ELIMINATION CAPACITY IN RELATION TO CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH CIRRHOSIS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6538698" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Prediction of fatality in fulminant hepatic failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3258578" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Prognostic indicators in alcoholic cirrhotic men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2734585" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6420303" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Caffeine: a model compound for measuring liver function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3371873" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3557314" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Overnight salivary caffeine clearance: a liver function test suitable for routine use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8832505" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The measurement of caffeine concentration in scalp hair as an indicator of liver function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14578861" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24714782" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Significance of the (13)C-caffeine breath test for patients with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3443824" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8301034" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8138268" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32440099" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2564460" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Lignocaine metabolite formation as a measure of pre-transplant liver function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1989297" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Functional state of the donor liver and early outcome of transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9047147" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
